BCIQ Profiles

Company Profile ReportTarget Profile Report
0730 Cytovia ECP
BioCentury & Getty Images

Emerging Company Profile

Cytovia: activating NK cells at the tumor site

Emerging Company Profile: With its R&D center up and running and a manufacturing facility by year-end, Cytovia aims to enter the clinic early 2022

Cytovia is leveraging its two NK cell platforms and at least 11 partnerships to enter the clinic next year with several therapies targeting both solid and liquid tumors.

Jul 30, 2021 | 8:52 PM GMT

After bolstering its management team with new

Read the full 796 word article

How to gain access

Continue reading with a
two-week free trial.